What Alfetim SR treats: main uses and benefits

Alfetim SR, an extended-release formulation of alprazolam, is applied in addressing conditions characterized by periods of heightened symptoms. The primary therapeutic domain is in addressing conditions characterized by periods of heightened symptoms, which commonly includes panic disorder. The formulation is considered relevant for easing symptoms that become more disruptive during flare-ups and is relevant when supportive symptom management is appropriate.

This medication generally supports patients by easing symptom clusters that may become intense or disruptive, such as those related to heightened physiological activity and systemic imbalance.

Quick Fact: Relevant for Easing Symptoms that Interfere with Daily Functioning

By supporting general well-being during symptomatic phases, Alfetim SR contributes to improved comfort and may assist with maintaining functional stability. It is commonly used to help provide supportive relief when symptoms interfere with routine activities. This approach may help patients cope more steadily with symptom fluctuations.

Alfetim SR is a prescription medicine indicated only for adult males for the management of symptoms associated with Benign Prostatic Hyperplasia (BPH). The eligibility for this medicine is strictly defined by government regulatory authorities, placing several prohibitions on use.

Contraindicated Populations

Use of Alfetim SR is absolutely prohibited in patients with moderate or severe hepatic (liver) impairment. It must also not be used if the patient has a history of orthostatic hypotension (low blood pressure upon standing) or a known hypersensitivity to alfuzosin or any tablet component.

Exclusions and Restrictions

The medicine is not indicated for use in women or in the pediatric population (children and adolescents). Use is also contraindicated when taken with potent CYP3A4 inhibitors or with any other alpha-1 adrenergic receptor antagonists.

Conditional Use

Specific conditions require caution. The medicine should be used with caution in patients with severe renal (kidney) impairment or mild hepatic impairment. Additionally, if angina pectoris symptoms appear or worsen during treatment, the medicine must be discontinued, as specified in the official labeling.

Interactions with other medicines and products

The official interaction profile for Alfetim SR is structured around metabolic interference and additive hemodynamic effects, resulting in specific regulatory constraints.

Formal Regulatory Restrictions

Interaction Type	Restrictions	Outcome Documented in Labels
Potent CYP3A4 Inhibitors	Contraindicated Combination	Significant increase in Alfuzosin exposure (AUC up to 3.2-fold), increasing adverse reaction risk.
Other Alpha-1 Antagonists	Contraindicated Combination	Risk of severe hypotension and syncope due to additive pharmacodynamic effects.

---

Other Documented Interactions and Constraints

Alfetim SR is principally metabolized by the CYP3A4 enzyme. Co-administration with Moderate CYP3A4 Inhibitors (e.g., Diltiazem) is documented to increase systemic exposure, requiring regulatory caution. Cimetidine is also documented to increase exposure by approximately 20%.

Pharmacodynamic Interactions occur with other vasodilators and blood pressure-lowering agents. Official caution is advised for co-administration with Antihypertensive Medications, Nitrates, and PDE5 Inhibitors due to the risk of symptomatic hypotension.

Population-Specific Constraint: The medicine is contraindicated for use in patients with moderate or severe hepatic impairment because reduced clearance is documented to result in a three- to four-fold increase in systemic exposure. The sustained-release tablet must be taken immediately after the same meal each day to avoid a documented 50% reduction in absorption.

Targeting Sympathetic alpha1-Adrenoceptors

Alfetim SR's action is defined by its role as a selective antagonist of the alpha1-adrenoceptors (alpha1-ARs). These are the biological targets responsible for mediating smooth muscle contraction when activated by the sympathetic nervous system. By preemptively binding to these receptors in tissues like the prostate and bladder neck, the compound blocks the transmission of the neural signal, which is the foundational step in its mechanism.

Inhibiting the Contraction Cascade

The blockade of the alpha1-receptor interrupts an intracellular cascade that relies on the mobilization of calcium ions (Ca^2+) to initiate contraction. This interference limits the molecular signal necessary to activate muscle fibers. The physiological consequence is a maintained reduction of smooth muscle tone in the lower urinary tract.

Sustained Pathway Modulation

The sustained-release (SR) formulation provides a continuous alpha1-blockade over 24 hours. This continuous action mediates the constant reduction of smooth muscle tension and outflow resistance, ensuring continuous modulation of the sympathetic pathway's effect on the lower urinary tract.

Official Administration Guidelines for Alfetim SR

Alfetim SR is an oral sustained-release (SR) tablet, and its correct use is governed by its specialized formulation, requiring specific timing and method of intake.

---

Standard Labeled Dosing and Administration

Usage Parameter	Standard Instruction
Route of Administration	Oral intake. The tablet is swallowed whole.
Standard Adult Dose	One 10 mg extended-release tablet once daily.
Dosing Frequency	Once daily (q.d.).
Timing & Food Condition	Must be taken with food, specifically immediately after the same meal each day (e.g., breakfast or dinner).
Administration Method	The tablet must not be crushed, chewed, split, or divided to maintain its prolonged-release action.

---

Population-Specific Use

• Older Adults (Age 65 years): The standard 10 mg once-daily dose is generally applied without a mandatory adjustment.
• Pediatric Population: Use of Alfetim SR is not indicated in children or adolescents.
• Severe Renal Impairment: Use in patients with severe renal impairment (creatinine clearance <30 mL/min) requires caution and may be restricted, due to limited clinical safety data and potential for increased drug exposure.

---

The overall protocol emphasizes consistency. The administration requirement of taking the whole tablet once daily with the same meal provides a stable, standardized procedure for correct intake, ensuring the controlled release of the medicine over the full dosing interval.

Research Evidence: Overview of Studies for Alfetim SR

---

Evidence for Use in Managing Lower Urinary Tract Symptoms (LUTS)

Research exploring Alfetim SR in the context of LUTS associated with Benign Prostatic Hyperplasia (BPH) primarily involves clinical studies that compare the investigational agent to an inactive substance (placebo). These research settings are often short-term, typically measuring changes over periods of up to three months. The studies monitored adult men presenting with conditions marked by functional limitations and urinary difficulties.

The core outcomes related to systemic or functional imbalance that were monitored included functional urinary symptom scores—patient-reported outcomes describing perceived discomfort and the impact of symptoms on daily functioning. Researchers also measured objective metrics, such as changes in the peak urinary flow rate (Q max). Research also includes comparative studies where the agent was evaluated against other alpha-blocker agents to assess outcome patterns. Studies describe patterns observed in the measured functional symptom scores, reporting how symptoms evolved in the observed populations during the study period.

---

Evidence for Use in Facilitating Ureteral Stone Expulsion

Research also examined Alfetim SR in the context of the spontaneous passage of ureteral stones, a research area often referred to as Medical Expulsive Therapy (MET). This evidence comes primarily from numerous systematic reviews and meta-analyses that have pooled findings from multiple controlled clinical trials. These studies were applied in research contexts involving fluctuating or unstable symptoms associated with conditions involving periods of heightened symptoms.

Studies explored outcomes describing episodic or acute changes, focusing on the proportion of patients who passed their stones (the stone-free rate) and the average time it took for the expulsion to occur. The evidence level for this context is frequently assessed as Moderate, reflecting its reliance on pooled data and variability among individual trials.

---

Areas of Research Uncertainty and Study Limitations

Most of the foundational evidence for Alfetim SR has been gathered from short-term trials. Consequently, there is limited information for long-term outcomes or the persistence of reported changes beyond these initial study periods. Furthermore, evidence level varies across studies, leading to mixed findings in certain areas. The results apply only to the populations studied, and research does not determine whether an individual will respond similarly. Areas where more research could contribute remain.

Common questions about Alfetim SR (FAQ)

---

Q: Are there any specific container or storage requirements (e.g., must be kept in the original bottle)?

Official regulatory documents indicate that Alfetim SR should be stored at controlled room temperature, away from moisture, heat, and direct light. The tablets should be kept in their original, tightly closed container and should not be frozen. This helps protect the sustained-release formulation from environmental damage.

---

Q: Is Alfuzosin a controlled substance?

The active ingredient in Alfetim SR, Alfuzosin, is not categorized as a controlled substance by major government regulatory agencies. It is a prescription-only medicine.

---

Q: How is the medication eliminated from the body (e.g., through kidneys or liver)?

According to official product information, the active compound Alfuzosin is primarily metabolized (processed) by the liver, specifically using the CYP3A4 enzyme. The majority of the processed compound is then eliminated via the feces, with a smaller portion excreted through the urine.

---

Q: Is it safe to take common cold and flu medications (like decongestants, NSAIDs) with this drug?

Official documentation advises caution when using Alfetim SR with other medicines that affect blood pressure, including certain alpha-adrenergic antagonists. Some common cold and flu medications containing sympathomimetic agents (like decongestants) may have their effects altered or may increase the risk of low blood pressure. It is important to review the use of any combination of medicines with a qualified healthcare professional.

---

Q: What is the rationale for using this medication in combination with other BPH treatments?

Regulatory indications for Alfetim SR cover the management of moderate to severe symptoms of benign prostatic hyperplasia (BPH) and for short-term use as an add-on therapy for Acute Urinary Retention (AUR). Official cautions are advised regarding combining Alfetim SR with other drugs, such as PDE5 inhibitors, due to the potential risk of symptomatic hypotension (low blood pressure). The use of any combination should be determined by a healthcare provider.

How to Store and Dispose of Alfetim SR

Storage and disposal instructions for Alfetim SR (Alfuzosin Hydrochloride extended-release tablets) are strictly defined by regulatory requirements to ensure product stability and safety.

Official Storage Conditions

The medication must be stored at Controlled Room Temperature (20 C to 25 C), with permissible excursions between 15 C and 30 C. The tablets must be kept in the original container, which should remain tightly closed, and protected from moisture and excessive heat; the product must not be frozen. A mandatory safety requirement is to keep Alfetim SR out of the sight and reach of children.

Disposal Requirements

Official regulatory guidance requires that unused or expired Alfetim SR be disposed of in accordance with local regulations. The product should not be flushed down the toilet. Disposal should utilize a drug take-back program when available, or by following FDA guidance for secure household trash disposal when a take-back option is not present.